You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Citation Tools

Article menu

Download PDFPDF

XML
Psoriatic arthritis
Original article
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Strand V, de Vlam K, Covarrubias-Cobos JA, et al
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
RMD Open 2019;5:e000806. doi: 10.1136/rmdopen-2018-000806